Stoke Therapeutics (STU:0GT) Beginning Cash Position : €143.81 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Beginning Cash Position?

Stoke Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2024 was €143.81 Mil.

Stoke Therapeutics's quarterly Beginning Cash Position increased from Jun. 2024 (€166.43 Mil) to Sep. 2024 (€174.84 Mil) but then declined from Sep. 2024 (€174.84 Mil) to Dec. 2024 (€143.81 Mil).

Stoke Therapeutics's annual Beginning Cash Position declined from Dec. 2022 (€137.32 Mil) to Dec. 2023 (€104.65 Mil) but then increased from Dec. 2023 (€104.65 Mil) to Dec. 2024 (€183.37 Mil).

Stoke Therapeutics Beginning Cash Position Historical Data

The historical data trend for Stoke Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Beginning Cash Position Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

183.04

254.45

137.32

104.65

183.37

Stoke Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Beginning Cash Position	Get a 7-Day Free Trial															174.73	176.65	166.43	174.84	143.81

Stoke Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Stoke Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

STOK:USA 0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Stoke Therapeutics Headlines

No Headlines